ResearcherUniversité Paris CitéActive in the last 2 years

Maxime Rémond

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7147-6936; OpenAlex author ID A5085219183. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

Clinical and molecular features of early onset pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.35135 ↗
Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? Co-author DOI 10.1016/j.esmoop.2022.100638 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Anna Pellat · 1 shared paper, 2022 · strength 0.20
- Paper Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? DOI 10.1016/j.esmoop.2022.100638 ↗
Romain Coriat · 1 shared paper, 2022 · strength 0.20
- Paper Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma? DOI 10.1016/j.esmoop.2022.100638 ↗
Anthony Tarabay · 1 shared paper, 2024 · strength 0.17
- Paper Clinical and molecular features of early onset pancreatic adenocarcinoma. DOI 10.1002/ijc.35135 ↗
Cristina Smolenschi · 1 shared paper, 2024 · strength 0.17
- Paper Clinical and molecular features of early onset pancreatic adenocarcinoma. DOI 10.1002/ijc.35135 ↗
Antoine Hollebecque · 1 shared paper, 2024 · strength 0.17
- Paper Clinical and molecular features of early onset pancreatic adenocarcinoma. DOI 10.1002/ijc.35135 ↗
Alice Boilève · 1 shared paper, 2024 · strength 0.17
- Paper Clinical and molecular features of early onset pancreatic adenocarcinoma. DOI 10.1002/ijc.35135 ↗
Michel Pierre Ducreux · 1 shared paper, 2024 · strength 0.17
- Paper Clinical and molecular features of early onset pancreatic adenocarcinoma. DOI 10.1002/ijc.35135 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.